Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: StockDung who wrote (2931)	10/28/2000 7:21:24 PM
From: out_of_the_loop	Respond to of 5582

That means that Eby's patent and Quigley's claims expire at that time so anyone can make zinc "anti-cold" lozenges. Gel Tech's patent was granted this spring and expires in the standard 20 or so years.

To: StockDung who wrote (2931)	10/28/2000 7:43:30 PM
From: DanZ	Read Replies (1) \| Respond to of 5582

Anyone can manufacture and sell zinc lozenges today without violating Eby's patent. The Dietary Supplement Health and Education Act of 1994 gives companies a loophole to sell zinc lozenges as dietary supplements. They just can't claim that their product reduces the duration or severity of the common cold. To make that claim, the manufacturer would have to pay Quigley a royalty. You can read all about DSHEA at crnusa.org This is one reason that Mad2's claim that Zicam is heading the same direction as Cold Eeze is flawed. Companies can't sell a nasal gel as a dietary supplement so they don't have a loophole that allows them to get around Gel Tech's patent. The competitive factors that hurt Quigley's sales don't plague Gum Tech.